Adenoviral Vectors for Liver Cancer—Clinical Trials
Ragai R. Mitry, Catherine E. Sarraf, Nagy A. Habib
Malignant tumors of the liver are among the commonest cancers in the world, with an estimated annual global incidence of 1,000,000 cases per year. This includes primary tumors such as hepatocellular carcinoma (HCC) and metastases in the liver from various primary sites, for example the colon-colorectal liver metastases (CLM). In most cases, especially with primary liver tumors, the prognosis is very poor and those with advanced disease are unlikely to survive more than three months. Moreover, many cases of HCC are beyond radical resection when detected, and treatment is rarely beneficial. Gene-based therapies are being developed for many diseases, including cancer, and these will involve augmentation of immunotherapeutic and/or chemotherapeutic approaches.